Randomized Controlled Trial
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Eur. Heart J. 2018 Oct 7; 39 (38): 3499-3507.
Randomized Controlled Trial
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2017 Oct 21; 390 (10105): 183318421833-1842.
Randomized Controlled Trial
Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
Ann. Intern. Med. 2020 Apr 21; 172 (8): 523-532.